Key result
Adjunctive use of abciximab during PCI resulted in major bleeding in 1.7% and thrombocytopenia in 3.9% of patients, with female gender and bail-out use identified as risk factors.
Why the study?
What are the clinical predictors of bleeding complications in patients receiving abciximab during PCI?
Population
344 consecutive patients who underwent percutaneous coronary intervention with adjunctive use of abciximab
Design
Cohort
Authors
Loading...
May inform bleeding risk discussions for abciximab in PCI; hypothesis-generating for refined selection pending prospective validation.
Cohort (n=344)
What are the clinical predictors of bleeding complications in patients receiving abciximab during PCI?
Female gender and bail-out use of abciximab are associated with an increased risk of bleeding complications during PCI.
Razakjr et al. (2005) conducted a cohort in Percutaneous coronary intervention (n=344). Abciximab was evaluated on Major bleeding. Adjunctive use of abciximab during PCI resulted in major bleeding in 1.7% and thrombocytopenia in 3.9% of patients, with female gender and bail-out use identified as risk factors.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: